Overview

A Phase II Study of Maintenance With Azacitidine in MDS Patients

Status:
Terminated
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
A phase II multicentre trial of maintenance with Azacitidine in MDS patients achieving complete or partial remission (CR or PR) after intensive chemoterapy. The primary objective is response duration (MDS or AML)
Phase:
Phase 2
Details
Lead Sponsor:
Groupe Francophone des Myelodysplasies
Collaborator:
Celgene Corporation
Treatments:
Azacitidine